Amyris is a biotechnology company making specialty ingredients and consumer products out of plant sugars that is headquartered in Emeryville, California and was founded in 2003 by
Jack Newman, Kinkead Reiling, Neil Renninger, and Vince Martin.
On October 12, 2006 Amyris announced completing their series A funding round with $20 million in funding from Khosla Ventures (lead investor), Kleiner Perkins Caufield & Byers (KPCB), and Texas Pacific Group Ventures (TPGV). At the time of receiving their series A funding the company appointed John Melo as the companies CEO. Jay D. Keasling, one of the founders of Amyris, made the following public statement regarding what the company plans on doing with their series A funding:
The completion of this financing validates the strength of Amyris' core technology and signals an important step in the company's growth. These new resources will enable the company to expand its capabilities to address major global health and energy challenges, thereby helping to fulfill the promise of synthetic biology.
On June 26, 2010 Amyris announced completing their series D funding round with $133 million in funding from Temasek Holdings (lead investor), Total, Procter & Gamble Company, and Cosan S.A..
On April 29, 2019 Amyris announced raising $34 million through the sale the private placement of common stock to existing investors. The president and CEO of Amris, John Melo, made the following statement regarding the companies private placement of common stock:
Our long-term investors continue to be encouraged by the performance of our products and technology. We believe they see our capabilities as being essential in disrupting large global markets by delivering the best products to meet consumer needs for natural and sustainable skin care, sweeteners and soon with highest quality and purity CBD. These funds support our plan to retire our May debt maturity and to continue growing our business.
In October 2011 Amyris acquired Draths Corporation for $7 million in stock. The company purchased Draths Corporation for their patents related to the production of synthetic materials using biotechnology and chemistry.